216 Chapter 7 research grants from private funds, as well as institutional grants, trial funding/ educational and travel funding from the following companies over the years: het Sikkelcelfonds, Pfizer, Baxter/Baxalta/Shire Takeda, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, Nordic Pharma and Roche, and has served as a member on steering boards of Roche and Bayer. All grants, awards and fees go to the Erasmus MC as an institution. All other authors have no competing interest relevant to the contents of this manuscript. Funding This research received funding from Roche Nederland B.V. and the SYMPHONY NWO-NWA consortium: grant agreement NWA.1160.18.038. Acknowledgement We would like to thank E. Hoogendijk, C.E. Schmidt, I. Cobzaru, R. Mansens, C.H. van Ommen, A.B. Mohseny and S. Meijer for their contributions to the PARTITURA consortium. PARTITURA aims to set up care pathways & patient journeys for patients with inherited bleeding disorders in the Netherlands. In order to achieve this goal, experts from multiple disciplines and institutes work together: Erasmus MC and Erasmus MC Sophia Children’s Hospital, project leadership and coordination; Amsterdam University Medical Centers with Emma Children’s Hospital; University Medical Center Groningen with Beatrix Children’s Hospital; University Medical Center Utrecht with Wilhelmina Children’s Hospital; Leiden University Medical Center with Willem-Alexander Children’s Hospital; Radboud University Medical Center with Amalia Children’s Hospital; Maastricht University Medical Center; Maxima Medical Center; Technical University Delft; Erasmus University Rotterdam; Netherlands Society of Hemophilia Patients (NVHP). Funding was made available for this investigator-initiated research project by Roche Nederland B.V. The SYMPHONY consortium 5, which aims to orchestrate personalized treatment in patients with bleeding disorders, is a unique collaboration between patients, health care professionals and translational and fundamental researchers specialized in inherited bleeding disorders, as well as experts from multiple disciplines. SYMPHONY aims to identify best treatment choice for each individual based on bleeding phenotype. In order to achieve this goal, workpackages have been organized according to three themes e.g. Diagnostics (workpackage 3&4), Treatment (workpackages 5-9) and Fundamental Research
RkJQdWJsaXNoZXIy MTk4NDMw